Breaks Categories: News

TuesdayFeb 21, 2023 11:19 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced upcoming participation in the Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2023 Forum taking place from Feb. 23-25 in San Diego, California, at the Marriott Marquis San Diego Marina. Founded in 1995, ACTRIMS is comprised exclusively of multiple sclerosis (“MS”) researchers and clinicians. “ACTRIMS provides us with an opportunity to interact with an esteemed community of leaders pushing the boundaries…

Continue Reading

TuesdayFeb 21, 2023 10:39 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financial, Corporate Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting on its second quarter of fiscal year 2023, the period that ended Dec. 31, 2022. Highlights of the report include the company closing the calendar year with nearly $11.5 million in cash and the completion of enrollment in the company’s phase 2 clinical trial in epidermolysis bullosa (“EB”). The report also noted that the company has seen advancement in its research using rare cannabinoids in the treatment of glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. “This…

Continue Reading

FridayFeb 17, 2023 12:31 pm

BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD

Psycheceutical Bioscience (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, has entered into an exclusive agreement with iNGENū Pty Ltd., an Australian-based contract research organization. The agreement calls for iNGENū to conduct ​two human ​clinical trials of BWVI’s patented NeuroDirect(TM) ketamine topical ​in Australia. The first, a phase 1 trial, is designed to study 20 people and evaluate the safety, tolerability and pharmacokinetics of a single dose of NeuroDirect ketamine; the second, a phase 2 trial, is designed to study 115 participants diagnosed with post-traumatic stress disorder (“PTSD”) to evaluate the effectiveness…

Continue Reading

ThursdayFeb 16, 2023 3:47 pm

BioMedNewsBreaks – Aesther Healthcare Acquisition Corp. and Ocean Biomedical Inc. (NASDAQ: OCEA) Announce Approved Business Combination

Aesther, a special purpose acquisition company (“SPAC”) and Ocean Biomedical Inc. (NASDAQ: OCEA), a next-generation biopharma company, recently announced stockholder approval of all proposals related to the previously disclosed proposed business combination between Aesther and Ocean. According to the update, the approvals were secured at a special meeting of stockholders held on Feb. 3, 2023. The combined company, Ocean Biomedical, and its Class A common stock commenced trading on the Nasdaq Capital Market under the symbol OCEA. “I’m pleased that the majority of shareholders have, through their votes in favor of going public, reaffirmed their belief in our vision for…

Continue Reading

WednesdayFeb 15, 2023 12:17 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Confirmation of NASDAQ Compliance

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has regained compliance with NASDAQ continued listing requirements. The company announced that it has received confirmation from the exchange that it is in compliance with the minimum bid price requirement of $1 per share; the company currently meets all other applicable criteria for continued listing. In September 2022, FSD Pharma was notified that it was not in compliance with the Listing Rules of the Nasdaq Stock Market. On…

Continue Reading

WednesdayFeb 15, 2023 10:58 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Report, Corporate Update for Q3

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) is reporting on its financial and corporate performance for the third fiscal quarter 2023. Highlights of the report include a focus on the company’s phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease. The company reports that the number of sites participating in the trial has reached four: three sites in the United States and one site in Canada. In addition, based on patient enrollment and interest in the study, the company plans to more than double the number of trial sites, from the planned 4 or…

Continue Reading

TuesdayFeb 14, 2023 12:58 pm

BioMedNewsBreaks – IBN to Shine the Spotlight on Health Equity in Clinical Trials Congress

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced its collaboration with Kisaco Research for its upcoming Health Equity in Clinical Trials Congress, which is slated to take place at the beautiful Hilton Boston Back Bay on Feb. 22-23, 2023. Kisaco is a leader in combining state-of-the-art conference production with high-impact networking to drive conversations between marquee organizations, policymakers, academic institutions, medtech and biopharma companies. The upcoming event aims to help facilitate change for underrepresented communities through industry action and technology across the animal health, beauty, health and wellness, AI and tech, drug development, women’s health, legal…

Continue Reading

TuesdayFeb 14, 2023 11:51 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, Anthony Voorhies, currently the head of the AditxtScore(TM) division, will serve as president of Pearsanta. Voorhies has over 20 years of clinical diagnostics and healthtech industry experience and, under his leadership, the AditxtScore(TM) division has successfully grown from inception to commercialization and revenues in just…

Continue Reading

TuesdayFeb 14, 2023 11:42 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse. “Alcohol intoxication is a common presentation in many patients who visit hospital emergency rooms, and I see this during every one of my shifts,” said Dr. Albert Wong, a member of FSD Pharma’s expert advisory committee and a psychiatrist in the emergency department at the Centre…

Continue Reading

TuesdayFeb 14, 2023 11:31 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec. 31, 2022. In the report, the company noted that it had received approval from an independent ethics committee in the Netherlands to begin the first-in-human dosing of its CYB004 through a protocol amendment to its ongoing phase 1 CYB004-E trial; CYB004 is the company’s proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule. The company is also making progress on its phase 1/2a clinical trial evaluating CYB003 for the potential treatment…

Continue Reading